Alan Cash of Terra Biological to Present Breakthrough Oxaloacetate Research at 2025 International ME/CFS Conference

Alan Cash of Terra Biological to Present Breakthrough Oxaloacetate Research at 2025 International ME/CFS Conference

The 2025 International ME/CFS Conference, hosted by the ME/CFS Research Foundation, is set to feature a pivotal presentation by Alan Cash, Chief Science Officer of Terra Biological LLC.

Scheduled for May 13 at 11:30 AM CEST, Cash will discuss the latest clinical findings on oxaloacetate supplementation as a promising intervention for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and post-COVID fatigue.

A Metabolic Approach to Chronic Fatigue

Oxaloacetate, a naturally occurring metabolite, has garnered attention for its potential to normalize disrupted energy metabolism in ME/CFS patients. Terra Biological’s recent randomized, open-label, clinical trial, published by Frontier in Neurology, demonstrated significant reductions in both physical and mental fatigue among trial participants. 

These findings suggest that Oxaloacetate CFS medical food may address the underlying metabolic dysfunctions associated with chronic fatigue syndromes, offering a novel therapeutic avenue for patients who have long suffered from limited treatment options.

Conference Details

  • Event: International ME/CFS Conference 2025
  • Date: May 12–13, 2025
  • Location: Harnack House, Max Planck Society, Berlin, Germany
  • Presentation: “Oxaloacetate Trials in ME/CFS and PCS” by Alan Cash
  • Time: May 13, 11:30 AM CEST 
The conference will be a hybrid event, allowing both in-person and virtual attendance. Registration is free and open to medical professionals, researchers, and interested members of the public. After the conference, Cash's presentation, as well as other featured speakers, will be available for viewing at https://events.mecfs-research.org/en/events/conference_2025

Alan Cash, Chief Science Officer and founder of Terra Biological LLC, a San Diego-based company specializing in oxaloacetate metabolic therapy research and development. With more than two decades of research into oxaloacetate, Cash has been instrumental in exploring its applications for various health conditions, including ME/CFS and long COVID. 

Terra Biological’s commitment to scientific innovation continues to pave the way for new treatments aimed at improving the quality of life for those affected by chronic fatigue syndromes.

Back to blog